Evofem restructures convertible notes; changes governing law, reissues under Section 3(a)(9)

Evofem Biosciences, Inc.

Modified eight series of senior convertible notes issued Dec 2022–Sep 2023; no new consideration paid.
Changed governing law from New York to Delaware; notes reissued under Securities Act Section 3(a)(9) exemption.
Conversion price set at $0.0635 per share; default interest rate 12%; beneficial ownership cap 4.99%.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.7

Evofem Biosciences, Inc. amended Restructuring Agreements with certain holders of the Company's previously issued securities (effective 2023-12-01).

Action: amendment
Agreement: notes offering
Counterparty: certain holders of the Company's previously issued securities
Effective: 2023-12-01

Exact text from the filing

On December 1, 2023, Evofem Biosciences, Inc. (the “Company”) entered into agreements with the holders (each a “Holder”) of certain of the Company’s previously issued securities (collectively, the “Restructuring Agreements”).

View on SEC.gov

Browse all material agreements →

Evofem Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-044012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.